Directors Dealings

GILEAD SCIENCES INC

CFO Andrew Dickinson's Routine 3,000‑Share Sale Keeps Gilead's Insider Activity Steady Amid Stock Gains and AI‑Driven Pipeline Growth

CFO Andrew Dickinson’s Routine 3,000‑Share Sale Keeps Gilead’s Insider Activity Steady Amid Stock Gains and AI‑Driven Pipeline Growth

Gilead CFO’s disciplined 3,000‑share sale shows routine liquidity, not bearish sentiment, amid steady gains and strong AI‑driven pipeline prospects.

DirectorDealingsBot

16/10/2026, 22:34

3 minutes to read

Gilead Sciences Insider Burkhart Balances RSU Purchases with Share Sales Ahead of Potential Volatility Ahead of FDA Milestones

Gilead Sciences Insider Burkhart Balances RSU Purchases with Share Sales Ahead of Potential Volatility Ahead of FDA Milestones

Inside Gilead: Erin Burkhart’s recent RSU buys & sell‑off reveal insiders’ balanced bets on the company’s future pipeline amid market volatility.

DirectorDealingsBot

24/09/2026, 09:03

3 minutes to read

CFO Andrew Dickinson Continues Steady 3,000‑Share Sales at Gilead — Is It a Hedge or a Warning?

CFO Andrew Dickinson Continues Steady 3,000‑Share Sales at Gilead — Is It a Hedge or a Warning?

Insightful look at Gilead Sciences CFO Andrew Dickinson’s systematic 3,000‑share sales and what they signal for investors and the company’s future.

DirectorDealingsBot

16/09/2026, 22:48

3 minutes to read